REPL
Price:
$11.535
Market Cap:
$788.09M
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise cause...[Read more]
Industry
Biotechnology
IPO Date
2018-07-20
Stock Exchange
NASDAQ
Ticker
REPL
According to Replimune Group, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 712.38M. This represents a change of 5.07% compared to the average of 677.99M of the last 4 quarters.
The mean historical Enterprise Value of Replimune Group, Inc. over the last ten years is 619.15M. The current 712.38M Enterprise Value has changed 11.41% with respect to the historical average. Over the past ten years (40 quarters), REPL's Enterprise Value was at its highest in in the June 2021 quarter at 1.83B. The Enterprise Value was at its lowest in in the September 2017 quarter at 0.
Average
619.15M
Median
482.96M
Minimum
305.45M
Maximum
1.26B
Discovering the peaks and valleys of Replimune Group, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 289.60%
Maximum Annual Enterprise Value = 1.26B
Minimum Annual Increase = -45.24%
Minimum Annual Enterprise Value = 305.45M
Year | Enterprise Value | Change |
---|---|---|
2024 | 515.99M | -45.24% |
2023 | 942.21M | 15.83% |
2022 | 813.46M | -35.53% |
2021 | 1.26B | 289.60% |
2020 | 323.88M | -4.86% |
2019 | 340.43M | -24.34% |
2018 | 449.93M | 47.30% |
The current Enterprise Value of Replimune Group, Inc. (REPL) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
757.22M
5-year avg
771.47M
10-year avg
619.15M
Replimune Group, Inc.’s Enterprise Value is less than Nuvalent, Inc. (6.03B), greater than Ventyx Biosciences, Inc. (119.81M), less than Ascendis Pharma A/S (7.09B), less than United Therapeutics Corporation (15.54B), greater than Nuvectis Pharma, Inc. (106.86M), greater than Lyra Therapeutics, Inc. (21.68M), greater than Kronos Bio, Inc. (14.25M), greater than Gossamer Bio, Inc. (309.65M), less than Kura Oncology, Inc. (1.25B), less than Protagonist Therapeutics, Inc. (2.35B), less than Merus N.V. (3.02B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Aerovate Therapeutics, Inc. (49.21M), less than Keros Therapeutics, Inc. (1.85B), less than Syndax Pharmaceuticals, Inc. (1.48B), greater than Mineralys Therapeutics, Inc. (602.46M), less than Crinetics Pharmaceuticals, Inc. (4.74B), less than NewAmsterdam Pharma Company N.V. (1.04B), greater than PureTech Health plc (314.94M),
Company | Enterprise Value | Market cap |
---|---|---|
6.03B | $6.11B | |
119.81M | $149.47M | |
7.09B | $7.27B | |
15.54B | $16.69B | |
106.86M | $124.97M | |
21.68M | $16.84M | |
14.25M | $57.33M | |
309.65M | $197.65M | |
1.25B | $1.28B | |
2.35B | $2.70B | |
3.02B | $3.46B | |
8.24B | $8.19B | |
49.21M | $79.60M | |
1.85B | $2.24B | |
1.48B | $1.58B | |
602.46M | $670.32M | |
4.74B | $4.99B | |
1.04B | $1.57B | |
314.94M | $498.68M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Replimune Group, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Replimune Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Replimune Group, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Replimune Group, Inc. (REPL)?
What is the 3-year average Enterprise Value for Replimune Group, Inc. (REPL)?
What is the 5-year average Enterprise Value for Replimune Group, Inc. (REPL)?
How does the current Enterprise Value for Replimune Group, Inc. (REPL) compare to its historical average?